Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:905-906 (16 April), doi:10.1136/bmj.330.7496.905-a
| The first 150 words of the full text of this article appear below. |
EDITORAppropriate self treatment is an important aspect of both the European and American healthcare systems.1 In August 2004 simvastatin 10 mg (Zocor Heart-Pro) became the first statin approved for over the counter sale by pharmacists for people at "moderate" risk of a major coronary event.2 Is this is another ill conceived example of "creeping privatisation" or a reasonable attempt to empower consumers?3 4
|
We compared the characteristics of people who when questioned expressed a willingness to buy simvastatin with those who did not. JQ, also a locum pharmacist, selected subjects who seemed likely to be among the target population as they entered one of three pharmacies in Bristol over 10 days in August 2004. An anonymised, self completion questionnaire was administered, with informed consent, to people who were not taking statins.
Four weeks after deregulation only one
Jerry Quill, fourth year medical student, University of Bristol
jdquill@yahoo.com
Richard Martin, senior lecturer in epidemiology and public health
Richard.Martin@bristol.ac.uk Department of Social Medicine, University of Bristol, Bristol BS8 2PR